Direct and Indirect Effects of Cytomegalovirus-Induced γδ T Cells After Kidney Transplantation
Overview
Affiliations
Despite effective anti-viral therapies, cytomegalovirus (CMV) is still associated with direct (CMV disease) and indirect effects (rejection and poor graft survival) in kidney transplant recipients. Recently, an unconventional T cell population (collectively designated as Vδ2(neg) γδ T cells) has been characterized during the anti-CMV immune response in all solid-organ and bone-marrow transplant recipients, neonates, and healthy people. These CMV-induced Vδ2(neg) γδ T cells undergo a dramatic and stable expansion after CMV infection, in a conventional "adaptive" manner. Similarly, as CMV-specific CD8+ αβ T cells, they exhibit an effector/memory TEMRA phenotype and cytotoxic effector functions. Activation of Vδ2(neg) γδ T cells by CMV-infected cells involves the γδ T cell receptor (TCR) and still ill-defined co-stimulatory molecules such as LFA-1. A multiple of Vδ2(neg) γδ TCR ligands are apparently recognized on CMV-infected cells, the first one identified being the major histocompatibility complex-related molecule endothelial protein C receptor. A singularity of CMV-induced Vδ2(neg) γδ T cells is to acquire CD16 expression and to exert an antibody-dependent cell-mediated inhibition on CMV replication, which is controlled by a specific cytokine microenvironment. Beyond the well-demonstrated direct anti-CMV effect of Vδ2(neg) γδ T cells, unexpected indirect effects of these cells have been also observed in the context of kidney transplantation. CMV-induced Vδ2(neg) γδ T cells have been involved in surveillance of malignancy subsequent to long-term immunosuppression. Moreover, CMV-induced CD16+ γδ T cells are cell effectors of antibody-mediated rejection of kidney transplants, and represent a new physiopathological contribution to the well-known association between CMV infection and poor graft survival. All these basic and clinical studies paved the road to the development of a future γδ T cell-based immunotherapy. In the meantime, γδ T cell monitoring should prove a valuable immunological biomarker in the management of CMV infection.
Tharmaraj D, Mulley W, Dendle C Front Immunol. 2024; 15:1490472.
PMID: 39660122 PMC: 11628869. DOI: 10.3389/fimmu.2024.1490472.
Chen X, Jin Z, Zhou P, Xie T, Jiang F, Tang Q BMC Pediatr. 2024; 24(1):587.
PMID: 39285316 PMC: 11403953. DOI: 10.1186/s12887-024-05051-z.
Fichtner A, Gauche L, Susal C, Tran T, Waldherr R, Krupka K Pediatr Nephrol. 2024; 40(2):491-503.
PMID: 39283519 PMC: 11666708. DOI: 10.1007/s00467-024-06487-2.
Mucosal T-cell responses to chronic viral infections: Implications for vaccine design.
Al-Talib M, Dimonte S, Humphreys I Cell Mol Immunol. 2024; 21(9):982-998.
PMID: 38459243 PMC: 11364786. DOI: 10.1038/s41423-024-01140-2.
Shi T, Burg A, Caldwell J, Roskin K, Castro-Rojas C, Chukwuma P J Clin Invest. 2023; 133(14).
PMID: 37227784 PMC: 10348771. DOI: 10.1172/JCI170191.